Paul M. Thompson

Paul M. Thompson focuses his practice on white-collar criminal defense, congressional investigations and appellate matters. He is a current member of the Firm-wide Management Committee and a former member of the Firm’s Executive Committee. From 2011 to 2015, Paul served as partner-in-charge of the Washington, DC office. Read Paul M. Thompson's full bio.

Firm/Organization: McDermott Will & Emery

Blogs: Antitrust Alert, FCA Update

Latest Articles

Antitrust Alert

The Latest: New DOJ Antitrust Division Policy Makes Compliance Programs More Critical than Ever

By Nicole Castle, Stefan M. Meisner & Paul M. Thompson on July 16, 2019

What Happened: Last week, the Antitrust Division reported that it has changed its Justice Manual to state that it will consider antitrust compliance at the charging stage in criminal antitrust investigations, instead of waiting for plea negotiation or the sentencing stage. Previously, the Antitrust Division had granted leniency only to the first whistleblower to come completely clean. Under the Antitrust Division’s policy reversal, this is no longer the only way to gain credit with the…

FCA Update

DOJ Guidance on Evaluation of Corporate Compliance Programs: Key Takeaways

By Tony Maida, Rebecca C. Martin, Michael W. Peregrine, Paul M. Thompson, Sarah E. Walters & Michael S. Stanek on May 9, 2019

Boards and management should make use of recent expanded guidance from the US Department of Justice to ensure that their compliance programs are considered “effective” if and when an investigation arises. Companies should affirmatively answer three fundamental questions in evaluating a compliance program: Is the compliance program well designed? Is the program being implemented effectively and in good faith? Does the compliance program work in practice? Click here to access the full article. …

FCA Update

Health Care Enforcement Quarterly Roundup – Q1 2019

By James A. Cannatti III, Tony Maida, Rebecca C. Martin, Laura McLane, Amandeep S. Sidhu, T. Reed Stephens, Paul M. Thompson, Theodore Alexander, Irene A. Firippis, Matthew M. Girgenti, Sean Hennessy, Sophia A. Luby, Drew Elizabeth McCormick & Jennifer B. Routh on April 26, 2019

In this first installment of the Health Care Enforcement Quarterly Roundup for 2019, we continue to monitor trends we identified in 2018 and introduce new enforcement efforts that are expected to persist in the coming year. In this Roundup, we focus on increased enforcement activity against electronic health record (EHR) companies, enforcement against individuals (with an acute focus on the telemedicine industry), lower court interpretations of the landmark Escobar ruling, developments related to the Granston Memo and dismissal of False…

FCA Update

Health Care Enforcement Quarterly Roundup | Q4 2018

By Tony Maida, Rebecca C. Martin, Laura McLane, Amandeep S. Sidhu, T. Reed Stephens, Paul M. Thompson, Theodore Alexander, Natalie Colvin, Irene A. Firippis, Matthew M. Girgenti, Sophia A. Luby & Jennifer B. Routh on January 30, 2019

This latest installment of the Health Care Enforcement Quarterly Roundup reflects on trends that persisted in 2018 and those emerging trends that will carry us into 2019 and beyond. Leading off with the US Department of Justice’s (DOJ) December announcement of its fiscal year 2018 False Claims Act (FCA) recoveries, it remains clear that the health care industry is a primary target of FCA enforcement activity. We also revisit the current state of implementation of…

FCA Update

Health Care Enforcement Quarterly Roundup | Q3 | September 2018

By Amy H. Kearbey, Tony Maida, Rebecca C. Martin, Laura McLane, Amandeep S. Sidhu, T. Reed Stephens, Paul M. Thompson, Theodore Alexander, Natalie Colvin, Irene A. Firippis, Matthew M. Girgenti, Sophia A. Luby & Jennifer B. Routh on October 8, 2018

In the latest installment of Health Care Enforcement Quarterly Roundup, we examine key enforcement trends in the health care industry that we have observed over the past few months. In this issue, we report on: Practical applications of recent guidance from the US Department of Justice (DOJ) A recent blow to DOJ’s effort to use the federal False Claims Act (FCA) to attack Medicare Advantage reimbursement Continued enforcement efforts at the state and federal level…

FCA Update

Health Care Enforcement Quarterly Roundup | Q2 | July 2018

By Stephen W. Bernstein, Emily J. Cook, Sandra M. DiVarco, Tony Maida, Rebecca C. Martin, Laura McLane, David S. Rosenbloom, Amandeep S. Sidhu, T. Reed Stephens, Paul M. Thompson, Monica Wallace, Natalie Colvin, Matthew M. Girgenti, Sophia A. Luby & McDermott Will & Emery on July 18, 2018

How will key trends and developments in health care policy and enforcement impact future litigants? In the latest Health Care Enforcement Quarterly Roundup, we address this question in the context of: Continued interpretations of the landmark Escobar case The latest guidance from US Department of Justice (DOJ) leadership regarding enforcement priorities The uptick in state and federal efforts to combat the opioid crisis Recent court decisions regarding the use of statistical sampling in False Claims…

FCA Update

Health Care Enforcement Quarterly Roundup | Q2 | July 2018

FCA Update

Register today! Health Care Enforcement Q2 Roundup Webinar

By Tony Maida, Laura McLane, Amandeep S. Sidhu & Paul M. Thompson on July 2, 2018

Health Care Enforcement Q2 Roundup Webinar Date: Tuesday, July 17, 2018 Time: 11:00 am PDT | 12:00 pm MDT | 1:00 pm CDT | 2:00 pm EDT REGISTER NOW How will recent developments and emerging trends related to health care fraud and abuse impact future investigation targets and litigants? Our upcoming Health Care Enforcement Quarterly Roundup webinar will address this critical question and discuss trends related to: Continued interpretations of landmark Escobar case Recent guidance…

FCA Update

New DOJ Task Force to Take on Opioid Crisis Using the FCA and Other Enforcement Tools

By Paul M. Thompson, Amandeep S. Sidhu & Matthew M. Girgenti on March 2, 2018

Earlier this week, the US Department of Justice (DOJ) launched a new front in its effort to combat the opioid crisis and explicitly stated that it will deploy the False Claims Act (FCA) as part of its offensive. In a press release and parallel speech delivered by Attorney General Jeff Sessions on February 28, 2018, DOJ announced the creation of the Prescription Interdiction & Litigation (PIL) Task Force. According to DOJ, the PIL Task Force…

Antitrust Alert

Jury Gives Auto Parts Manufacturer a Pass on DOJ Conspiracy Claims

By Stefan M. Meisner, Lisa A. Peterson, Mary Strimel & Paul M. Thompson on December 12, 2017

On November 29, 2017, a Japanese auto parts manufacturer and its US subsidiary defeated the US Department of Justice’s claims that the companies conspired with others to fix prices and rig bids for automotive body sealing products. The case involved a rare trial involving criminal antitrust charges. After 13 days of trial, a jury returned a not-guilty verdict for Tokai Kogyo Co. Ltd. and its subsidiary, Green Tokai Co. Ltd. Continue Reading.…

Paul M. Thompson

The Latest: New DOJ Antitrust Division Policy Makes Compliance Programs More Critical than Ever

DOJ Guidance on Evaluation of Corporate Compliance Programs: Key Takeaways

Health Care Enforcement Quarterly Roundup – Q1 2019

Health Care Enforcement Quarterly Roundup | Q4 2018

Health Care Enforcement Quarterly Roundup | Q3 | September 2018

Health Care Enforcement Quarterly Roundup | Q2 | July 2018

Health Care Enforcement Quarterly Roundup | Q2 | July 2018

Register today! Health Care Enforcement Q2 Roundup Webinar

New DOJ Task Force to Take on Opioid Crisis Using the FCA and Other Enforcement Tools

Jury Gives Auto Parts Manufacturer a Pass on DOJ Conspiracy Claims

Company

Support

New to the Network